MCAM and graft versus host disease: Preclinical and clinical studies have reported that: CD146+CD271+ MSCs demonstrate superior bone repair and angiogenesis in fracture models [185]; CD200+ placental MSCs show enhanced efficacy in reducing inflammation in graft-versus-host disease (GvHD) [186]; UC-MSCs, characterized by CD54+ and low HLA-DR expression, have produced favorable outcomes in autoimmune and inflammatory indications such as Crohn’s disease and multiple sclerosis [127].